Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Financials
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Cboe Europe  -  08:45:34 2023-01-27 am EST
10589.00 GBX   -0.52%
01/26US FDA Cancels Emergency Use Nod For AstraZeneca's COVID-19 Drug
MT
01/26ADRs End Higher; AstraZeneca, Diageo Trade Actively
DJ
01/26AstraZeneca loses emergency use authorisation for Evusheld
AN
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 132 331131 461181 878203 927203 927-
Enterprise Value (EV)1 144 340143 328206 261227 763224 505219 719
P/E ratio 97,9x41,0x1 468x51,0x28,0x21,7x
Yield 2,78%2,80%2,44%2,24%2,31%2,41%
Capitalization / Revenue 5,43x4,94x4,86x4,59x4,38x4,00x
EV / Revenue 5,92x5,38x5,51x5,12x4,82x4,31x
EV / EBITDA 21,6x17,2x27,2x16,4x13,9x11,4x
Enterprise Value (EV) / FCF 72,5x37,3x42,3x30,5x24,1x19,5x
FCF Yield 1,38%2,68%2,36%3,28%4,15%5,14%
Price to Book 10,00x8,41x4,24x5,23x4,88x4,32x
Nbr of stocks (in thousands) 1 311 9131 312 6601 549 1591 549 8001 549 800-
Reference price (USD) 101100117132132132
Announcement Date 02/14/202002/11/202102/10/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 24 38426 61737 41744 46346 56450 988
EBITDA1 6 6868 3117 58613 92516 19019 295
Operating profit (EBIT)1 6 4367 3409 92813 71815 30417 888
Operating Margin 26,4%27,6%26,5%30,9%32,9%35,1%
Pre-Tax Profit (EBT)1 1 5483 916-2653 6338 56611 780
Net income1 1 3353 1961124 0277 77010 046
Net margin 5,47%12,0%0,30%9,06%16,7%19,7%
EPS2 1,032,440,082,584,696,06
Free Cash Flow1 1 9903 8384 8727 4639 32811 283
FCF margin 8,16%14,4%13,0%16,8%20,0%22,1%
FCF Conversion 29,8%46,2%64,2%53,6%57,6%58,5%
Dividend per Share2 2,802,802,872,953,053,16
Announcement Date 02/14/202002/11/202102/10/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 11 39010 77110 98211 32510 65411 174
EBITDA1 2 1871 8962 5792 966--
Operating profit (EBIT)1 3 9613 3653 4132 9343 3243 622
Operating Margin 34,8%31,2%31,1%25,9%31,2%32,4%
Pre-Tax Profit (EBT)1 5532479222 0191 6741 900
Net income1 3863601 6401 8661 3381 519
Net margin 3,39%3,34%14,9%16,5%12,6%13,6%
EPS2 0,250,231,051,04--
Dividend per Share2 -0,93-2,46--
Announcement Date 04/29/202207/29/202211/10/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 12 00911 86724 38323 83620 57715 792
Net Cash position1 ------
Leverage (Debt / EBITDA) 1,80x1,43x3,21x1,71x1,27x0,82x
Free Cash Flow1 1 9903 8384 8727 4639 32811 283
ROE (Net Profit / Equities) 35,6%36,7%27,5%26,2%28,2%30,1%
Shareholders' equity1 3 7528 70440715 36527 52533 386
ROA (Net Profit / Asset) 2,19%4,99%8,77%5,09%9,00%10,7%
Assets1 61 01564 0531 27779 18186 37294 274
Book Value Per Share2 10,111,927,725,127,030,5
Cash Flow per Share2 2,283,664,186,527,738,97
Capex1 9799611 0911 5081 6121 761
Capex / Sales 4,01%3,61%2,92%3,39%3,46%3,45%
Announcement Date 02/14/202002/11/202102/10/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (GBP) 164 960 715 193
Capitalization (USD) 203 927 106 751
Net sales (USD) 37 417 000 000
Number of employees 83 100
Sales / Employee (USD) 450 265
Free-Float 96,5%
Free-Float capitalization (GBP) 159 118 556 368
Free-Float capitalization (USD) 196 704 935 430
Avg. Exchange 20 sessions (USD) 14 808 396 516
Average Daily Capital Traded 8,98%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA